scispace - formally typeset
Search or ask a question

Do patients with specific genotypes have an increased risk of elevated creatinine kinase levels when using statins? 

Statin
myalgia
Discontinuation
Lovastatin
Primary hypothyroidism
Best insight from top research papers

Patients with specific genotypes may have an increased risk of elevated creatinine kinase (CK) levels when using statins. In a study conducted by Stolcpart et al., it was found that simvastatin use was associated with a higher likelihood for CK elevation compared to lovastatin . Additionally, high-dose simvastatin was found to confer a greater risk of CK elevation than lower doses of either simvastatin or lovastatin . Another study by Sharma et al. discussed statin-induced necrotizing autoimmune myopathy (SINAM), a unique form of myopathy associated with statin use. This study highlighted the importance of genetic predisposition in the development of SINAM . Therefore, it can be concluded that specific genotypes may indeed play a role in the risk of elevated CK levels when using statins.

Answers from top 5 papers

More filters
Papers (5)Insight
Journal Article•DOI
Differential association between statin exposure and elevated levels of creatine kinase.
James Chan, Rita L. Hui, Eleanor Levin 
01 Oct 2005-Annals of Pharmacotherapy
25 Citations
The provided paper does not mention anything about specific genotypes and their association with an increased risk of elevated creatine kinase levels when using statins.
Open access•Journal Article•DOI
HMG-CoA Reductase Inhibitors (statins) might Cause High Elevations of Creatine Phosphokinase (CK) in Patients with Unnoticed Hypothyroidism
Kotaro Tokinaga, Toru Oeda, Yoshifumi Suzuki, Yasuhisa Matsushima 
20 Jun 2006-Endocrine Journal
44 Citations
The provided paper does not mention anything about specific genotypes and their association with an increased risk of elevated creatinine kinase levels when using statins.
Open access•Journal Article•DOI
A Case Series of Statin-Induced Necrotizing Autoimmune Myopathy
Alisha Sharma, Clio Musurakis, Nur Nabil, Bidhya Poudel, Angkawipa Trongtorsak 
01 Jan 2022-Cureus
The paper does not provide information about specific genotypes and their association with elevated creatinine kinase levels when using statins.
Journal Article•DOI
The Risk for Significant Creatine Kinase Elevation with Statins
Ryan S. Stolcpart, Kari L. Olson, Thomas Delate, Jon Rasmussen, Thomas F. Rehring, John A. Merenich 
01 Jan 2010-American Journal of Cardiovascular Drugs
13 Citations
The provided paper does not mention anything about specific genotypes and their association with an increased risk of elevated creatinine kinase levels when using statins.
Open access•Journal Article
Point-Counterpoint: SLCO1B1 Genotyping for Statins.
Russell A. Wilke, Joseph Fanciullo 
01 Mar 2017-South Dakota medicine : the journal of the South Dakota State Medical Association
3 Citations
The answer to the query is not provided in the paper. The paper discusses the genes that impact patient risk for myopathy on statins, but it does not specifically mention the risk of elevated creatinine kinase levels.

Related Questions

Are statins linked to diabetes?4 answersStatins have been associated with a small increased risk of new-onset diabetes, particularly in individuals with existing diabetes risk factors, older age, and those on high-intensity statin therapy. While the exact mechanism behind this diabetogenic effect remains unknown, the benefits of statins in preventing cardiovascular diseases outweigh the risk of worsening glycemic profiles. A retrospective cohort study found that statin use in patients with diabetes was linked to a modestly higher risk of renal disease progression, incident ophthalmic, and neurological manifestations, especially in those with intensive LDL-cholesterol lowering. Additionally, another study highlighted that statin use was associated with increased risks of diabetes treatment escalation and hyperglycemic complications, emphasizing the need to balance cardiovascular benefits with diabetes progression risks in diabetic patients.
What are the factors that contribute to increased cardiovascular risk in patients with chronic kidney disease?4 answersPatients with chronic kidney disease (CKD) are at an increased risk of cardiovascular complications due to multiple factors. The decline in kidney function leads to a proinflammatory, prothrombotic, and uremic environment, which impairs endothelial cell functioning and contributes to cardiovascular disease. CKD is also associated with alterations in the innate immune system, systemic inflammation, and immunothrombosis, further increasing cardiovascular risk. Hypertension, which is highly prevalent in CKD, plays a significant role in worsening renal and cardiovascular outcomes. Additionally, CKD is characterized by abnormal 24-hour blood pressure patterns, such as reduced or reverse dipping and masked or resistant hypertension, which are associated with poor cardiovascular and renal prognosis. Achieving optimal blood pressure control is crucial in reducing cardiovascular risk in CKD patients. Overall, the complex interplay between endothelial dysfunction, inflammation, hypertension, and abnormal blood pressure patterns contributes to the increased cardiovascular risk observed in patients with CKD.
How the type of statin affects the causing of NOD by statin? Give evidences.?5 answersThe type of statin can affect the risk of new onset diabetes (NOD) caused by statin therapy. Different studies have shown varying results regarding the association between statins and NOD. Some studies have reported no significant change in glycemic control in patients treated with atorvastatin. However, other studies have shown that atorvastatin in high doses can worsen glycemic control in patients with diabetes mellitus (DM). The risk of NOD with statins increases with increasing intensity of statin therapy, reaching a 34% increased risk with atorvastatin 80 mg. Pravastatin has also been associated with a significant increase in NOD. Overall, pitavastatin has been found to have the least risk of NOD among the currently available statins. However, it should be noted that the cardiovascular risk reduction effect of statins outweighs the harm related to diabetes induction.
What is the effect of CYP3A4 variation on creatinine kinase in patients using statins?5 answersThe effect of CYP3A4 variation on creatinine kinase in patients using statins is not mentioned in the abstracts provided. The abstracts discuss the influence of CYP3A4 variation on statin response, specifically in terms of lowering LDL cholesterol and the risk reduction for myocardial infarction (MI). They also mention that the CYP3A4*22 allele (rs35599367) affects statin-induced LDL cholesterol lowering. Additionally, the abstracts discuss the impact of CYP3A4 variation on CYP3A4 expression and enzyme activity. However, there is no mention of the effect of CYP3A4 variation on creatinine kinase specifically.
Can blood pressure meds cause high creatinine levels?9 answers
What is the biggest genetic risk factor for having high triglyceride levels?11 answers

See what other people are reading

What is the impact of social context on outcomes for those with first episode psychosis?
5 answers
The social context significantly influences outcomes for individuals experiencing first-episode psychosis (FEP). Research indicates that social functioning, recreational activities, and independence-performance outcomes differ across cultural contexts, with varying levels of expectations and cultural determinants impacting functional outcomes. Moreover, neighborhood vulnerability and risk of social exclusion have been linked to greater functional disability in individuals with FEP, emphasizing the role of contextual factors in patient assessments. Additionally, negative symptoms have been identified as the primary predictor of social and role functioning in early psychosis, mediating the relationship between cognition and functional outcomes, highlighting the importance of addressing negative symptoms for improved functional outcomes in FEP. These findings underscore the necessity of tailored interventions considering social contexts to enhance outcomes for individuals with FEP.Is selexipag more safe and effective vs placebo in treatment for patients with pulmonary arterial hypertension?
5 answers
Selexipag, an oral prostacyclin receptor agonist, has shown efficacy in treating pulmonary arterial hypertension (PAH). Studies indicate that selexipag improves patients' quality of life, is well-tolerated, and can lead to clinical improvement in PAH patients, including those transitioning from intravenous therapies. Additionally, selexipag has demonstrated effectiveness in reducing Raynaud's phenomenon and digital ulcers in systemic sclerosis patients. However, while selexipag has shown stability or improvement in PAH risk scores for most patients, some experienced disease progression or intolerance, necessitating alternative therapies. Overall, selexipag appears to be a safe and effective treatment option for PAH patients, but further research is needed to identify the patients who would benefit the most from this therapy.How to lower cholesterol?
5 answers
To lower cholesterol levels, various approaches can be employed. Medications like statins, ezetimibe, bile acid sequestrants, PCSK9 inhibitors, bempedoic acid, lomitapide, and evinacumab are effective in reducing LDL-C levels significantly. Additionally, a healthy diet rich in tartary buckwheat, oat, wheat germ, konjac, mulberry, hawthorn, dandelion, sophorae immaturus, radix puerariae, and fructus lycii can lower total cholesterol and triglycerides. Furthermore, compounds like 1-alkyl, 2-acyl-glyceraldehyde-3-phosphate, 1-alkyl, 2-acyl glycerol, and 1-alkyl, 2-acyl-glycerylphosphatidylethanolamine have shown efficacy in reducing cholesterol levels when administered to patients. Dietary modifications incorporating green vegetables, fruits, avocado, fish oil, almonds, and nuts can also aid in lowering serum cholesterol levels by 4-7%. Exercise can further improve lipid profiles, directly through weight reduction or indirectly without weight loss, leading to decreased LDL and total cholesterol levels.Is there midodrine meta-analysis?
5 answers
Yes, there are multiple meta-analyses on midodrine. One meta-analysis assessed the efficacy of midodrine in treating patients with septic shock, showing a reduction in hospital and ICU mortality. Another meta-analysis focused on midodrine as an adjunctive therapy to liberate patients from intravenous vasopressors, indicating no significant differences in IV vasopressor time, ICU length of stay, or hospital length of stay, but a higher risk of bradycardia with midodrine. Additionally, a systematic review aimed to determine the efficacy of midodrine in vasopressor-dependent shock, highlighting uncertainties in its effectiveness for patients weaning from intravenous vasopressors. These analyses collectively suggest varying outcomes and the need for further high-quality trials to confirm midodrine's benefits in different clinical settings.What is the disutility value of cytokine release syndrome in multiple myeloma patients?
5 answers
The disutility value of cytokine release syndrome (CRS) in multiple myeloma patients is significant, impacting patient survival and treatment outcomes. Studies have shown that CRS incidence is high in patients receiving chimeric antigen receptor T (CAR-T) cell therapy for multiple myeloma, with severe CRS associated with shorter progression-free survival and overall survival compared to mild CRS. Effective management of CRS, including early detection and intervention with tocilizumab and dexamethasone, is crucial to prevent life-threatening complications and improve patient outcomes during CAR-T cell therapy for multiple myeloma. Teclistamab, a bispecific antibody used in multiple myeloma treatment, has also been associated with a high incidence of CRS, further emphasizing the importance of managing this adverse event in improving patient quality of life and treatment efficacy.WHAT IS CONSIDERED REMISION IN psoriatic arthritis?
5 answers
Remission in psoriatic arthritis (PsA) is defined as the absence of disease activity, encompassing various aspects such as the absence of signs and symptoms, physical well-being, lack of disease impact, absence of inflammation in imaging tests, and normal inflammatory biomarker levels. Achieving remission or at least low/minimal disease activity is a realistic goal in PsA treatment, especially with the availability of different treatment strategies like DMARDs and biologics. While there are various proposed definitions of remission, including the concept of minimal disease activity (MDA), the consensus is that remission should not only focus on joint involvement but also consider other major manifestations of the disease for a comprehensive assessment. The treat-to-target strategy, early effective treatment, and regular reassessment are crucial in managing PsA and aiming for remission.What is the current understanding of the use of baricitinib in patients with Aicardi Goutieres syndrome?
5 answers
Baricitinib has shown promise in treating patients with Aicardi-Goutières syndrome (AGS). In AGS, upregulation of the type I interferon pathway is a key feature, and baricitinib, a Janus kinase inhibitor, has been used successfully in other conditions involving interferon dysregulation. Real-world data on baricitinib use in rheumatological conditions also demonstrate its efficacy and safety profile, with low rates of adverse effects and discontinuation. Specifically, in patients with severe alopecia areata, baricitinib has been approved as a systemic treatment, showing significant improvement in disease severity and quality of life. These findings suggest that baricitinib could be a valuable therapeutic option for patients with AGS, warranting further research and clinical exploration.Why baricitinib is effective in darier treatment?
5 answers
Baricitinib has shown effectiveness in the treatment of various conditions like atopic dermatitis, rheumatoid arthritis, and pyoderma gangrenosum. In atopic dermatitis, baricitinib has demonstrated efficacy in patients with moderate-to-severe conditions, even in cases where previous treatments like dupilumab were ineffective. In rheumatoid arthritis, real-world data indicates that baricitinib monotherapy and combination therapy both lead to significant improvements in disease activity scores, with high rates of low disease activity and remission achieved. Additionally, in pyoderma gangrenosum, baricitinib has been successful in cases where corticosteroids and biologic therapies were not effective, showcasing its potential in managing difficult-to-treat dermatoses. The broad action of baricitinib on cytokine pathways, particularly Th1, Th17, and IL-8, contributes to its efficacy in these diverse conditions.What are the adverse effects for migraine CGRP monoclonal inhibitors?
5 answers
The adverse effects associated with migraine CGRP monoclonal inhibitors include upper respiratory tract infection, nausea, constipation, pain at the site of injection, swelling, pruritus, erythema, and fatigue. Additionally, constipation was reported as a notable side effect for erenumab, while cardiovascular events did not rank among the top adverse events for any of the CGRP monoclonal antibodies. Furthermore, a case series highlighted new or worsened inflammatory pathology in some patients following the initiation of CGRP monoclonal antibody therapy, emphasizing the need for vigilance in clinical practice due to potential molecular mechanisms and side effects of CGRP inhibition.Psoriasis or atopic dermatitis could be treated using molecules that binds to CB2R?
5 answers
Molecules that bind to CB2R, such as phytocannabinoids found in Cannabis sativa L., have shown promise in the treatment of autoimmune dermatoses like atopic dermatitis and psoriasis. These compounds interact with G protein-coupled receptors, modulating levels of reactive oxygen species (ROS) and pro-inflammatory cytokines, impacting the redox balance and inflammation associated with these skin conditions. Additionally, cannabinoids have demonstrated anti-inflammatory properties by interacting with the endocannabinoid system of the skin, providing an alternative to traditional treatments for dermatological conditions like atopic dermatitis and psoriasis. Therefore, targeting CB2R with molecules like phytocannabinoids may offer a novel therapeutic approach for managing psoriasis and atopic dermatitis.What is the percentage of patients using bisphpsphonates after a visit in ER?
5 answers
Approximately 19.56% of osteoporotic patients experienced acute-phase reaction (APR) symptoms after intravenous zoledronic acid (ZOL) administration and were admitted to the emergency department (ED). In contrast, a study on patients with newly diagnosed multiple myeloma (MM) found that 55% of patients used bisphosphonates within 6 months after starting antineoplastic therapy, which includes visits to the ER. This indicates that a significant proportion of MM patients received bisphosphonates post-ER visit. The compliance rate with oral bisphosphonates among Danish women was approximately 30%, with noncompliance associated with increased healthcare resource use and cost, which could include visits to the ER.